Search

Your search keyword '"Roxana Schillaci"' showing total 53 results

Search Constraints

Start Over You searched for: Author "Roxana Schillaci" Remove constraint Author: "Roxana Schillaci" Topic medicine Remove constraint Topic: medicine
53 results on '"Roxana Schillaci"'

Search Results

1. Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.

2. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.

3. Abstract P6-20-14: Neutralizing soluble tumor necrosis factor alpha overcomes trastuzumab-resistant breast cancer immune evasion by downregulating mucin 4, improving NK cell function and decreasing myeloid-derived suppressor cells in tumor microenvironment

4. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy

5. SUN-122 Nuclear PDCD4 Expression Predicts Good Clinical Outcome in Luminal A-Like and Luminal B-Like Breast Cancer Subtypes

6. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer

7. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis

8. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer

9. FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: its Relationship With TGF-β1 and NF-κB Pathways

10. Nuclear ErbB-2 activity modulates the interferon signaling pathway in breast cancer cells resistant to anti-ErbB-2 therapies

11. Halting Retrograde Transport Excludes ErbB-2 From the Nucleus Abrogating Tumor Growth in Triple Negative Breast Cancer

12. Androgen Receptor Highjacks ErbB-2 Nuclear Function to Induce Triple Negative Breast Cancer Growth

13. Abstract 1913: Soluble TNFα blockade overcomes lapatinib resistance and induces an innate immune response in HER2-positive breast cancer

14. Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

15. p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth

16. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy

17. Juvenile exposure to a high fat diet promotes behavioral and limbic alterations in the absence of obesity

18. A Brucella spp. protease inhibitor limits antigen lysosomal proteolysis, increases cross-presentation, and enhances CD8+ T Cell responses

19. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer

20. Transactivation of ErbB-2 induced by tumor necrosis factor α promotes NF-κB activation and breast cancer cell proliferation

21. Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, andin VivoDevelopment of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways

22. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis

23. Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride

24. Insulin-Like Growth Factor-1 Receptor Regulation in Activated Human T Lymphocytes

25. Abstract 1195: TNFα induces multiresistance to HER2-targeted TNFα induces multiresistance to HER2-targeted therapies in HER2-positive breast cancer

26. Early effects of insulin-like growth factor-1 in activated human T lymphocytes

27. Downregulation of Insulin-like Growth Factor-1 Receptor (IGF-1R) Expression in Human T Lymphocyte Activation

28. Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2

29. Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4 + T cells

30. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

31. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model

32. Anti-Inflammatory activity of 11β-hydroxypregna-1,4-diene-3,20-dione

33. Inhibitory effect of 11β-hydroxypregna-l,4-diene-3,20-dione (ΔHOP) on lymphocyte proliferation

34. Abstract 1346: Immunotherapy against breast cancer based on Stat3 blockade

35. Abstract 2265: Stat3 and ErbB-2 interaction in breast cancer metastasis

36. Abstract 712: TNFα-induced MUC4 elicits trastuzumab resistance in ErbB-2-positive breast cancer

37. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation

38. Insulin Effect on Interleukin 1 (IL-1) and Interleukin 6 (IL-6) Production by Lipopolysaccharide-Stimulated Human Monocytes

39. P36 Silencing of IGF-IR and IGF-I induce antitumoral immune response in breast cancer model

40. Co-operative effect between insulin-like growth factor-1 and interleukin-2 on DNA synthesis and interleukin-2 receptor-alpha chain expression in human lymphocytes

41. Subject Index Vol. 59, 2003

42. 1002 Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Tumor Necrosis Factor Alpha

43. Abstract 1549: Targeting Stat3 induces senescence in breast cancer cells and elicits an immune response inhibiting tumor growth and metastasis

44. Abstract 2305: miR-16 is a tumor suppressor in progestin-induced breast cancer

45. Corrigendum to 'Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer' [Steroids 76 (2011) 381–392]

46. Abstract 3982: Deregulation of tumor-suppressive miR-16 through progestin-mediated oncogenic signaling contributes to breast cancer development

47. Abstract 2174: Progesterone receptor, AP-1 and Stat3 cooperative transcriptional complex in breast cancer

48. Abstract 4614: Progesterone receptor and ErbB-2 crosstalk in breast cancer

49. Abstract 2399: Inhibition of murine breast cancer growth by immunization with tumor cells transfected with a dominant negative vector of Stat3

50. Tumor necrosis factor transactivates ErbB2 in breast cancer cells

Catalog

Books, media, physical & digital resources